Literature DB >> 24481146

Dapagliflozin approved for type 2 diabetes.

Kate Traynor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24481146     DOI： 10.2146/news140013

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN： 1079-2082            Impact factor:   2.637


× No keyword cloud information.
  2 in total

1.  Euglycemic diabetic ketoacidosis caused by dapagliflozin: A case report.

Authors:  Yu-Mou Chou; Chen-June Seak; Zhong Ning Leonard Goh; Joanna Chen-Yeen Seak; Chen-Ken Seak; Chih-Chuan Lin
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

2.  Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial.

Authors:  Chieh-Hsiang Lu; Kyung Wan Min; Lee-Ming Chuang; Satoshi Kokubo; Satoshi Yoshida; Bong-Soo Cha
Journal:  J Diabetes Investig       Date:  2015-10-14       Impact factor: 4.232
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.